A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : PDE5i / phosphodiesterase type 5 inhibitors

[Related PubMed/MEDLINE]
Total Number of Papers: 310
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PDE5i  (>> Co-occurring Abbreviation)
Long Form:   phosphodiesterase type 5 inhibitors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2022 A prospective randomized controlled study on scheduled PDE5i and vacuum erectile devices in the treatment of erectile dysfunction after nerve sparing prostatectomy. ED, EF, IIEF-5, NSRP, OAD, PLNES, VED
2022 Autologous Immune Cell-Based Regenerative Therapies to Treat Vasculogenic Erectile Dysfunction: Is the Immuno-Centric Revolution Ready for the Prime Time? ED, PBMNC, PRP, SCT
2022 Bilateral neurosensory retinal detachment secondary to tadalafil treatment. NRD, OCT
2022 Daily low dose of tadalafil improves pain and frequency in bladder pain syndrome/interstitial cystitis patients. BPS/IC, OSS, QoL
2022 Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat. PAH, sGC
2022 Echocardiographic Evaluation of Initial Ambrisentan Plus Phosphodiesterase Type 5 Inhibitor on Right Ventricular Pulmonary Artery Coupling in Severe Pulmonary Arterial Hypertension Patients. 6MWD, NT-proBNP, PAH, RHC, RVPAC, WHO-FC
2022 GPX4 Alleviates Diabetes Mellitus-Induced Erectile Dysfunction by Inhibiting Ferroptosis. cGMP, DMED, GPX4-LV, NO, RhoA, ROCK
2022 Hydrogen Peroxide Stimulates Dihydrotestosterone Release in C2C12 Myotubes: A New Perspective for Exercise-Related Muscle Steroidogenesis? DHT, HSD, ROS, TAD
2022 Is tadalafil associated with decreased risk of major adverse cardiac events or venous thromboembolism in men with lower urinary tract symptoms? LUTS, MACE, VTE
10  2022 Male Sexual Dysfunction and Infertility in Spinal Cord Injury Patients: State-of-the-Art and Future Perspectives. ED, EEJ, ICI, PP, PVS, SCI, VEDs
11  2022 Medications for the treatment of pulmonary arterial hypertension: a systematic review and network meta-analysis. ERA, PAH
12  2022 Non-Coding RNAs: New Dawn for Diabetes Mellitus Induced Erectile Dysfunction. circRNAs, DM, ED, lncRNAs, miRNAs, ncRNAs, piRNAs, sncRNAs
13  2022 Phosphodiesterase 5 inhibitor suppresses prostate weight increase in type 2 diabetic rats. bFGF, HIF-1alpha, IGF-1, IL, LETO, OLETF, T2D, TGF-beta, TNF-alpha
14  2022 Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study. FVC
15  2022 Phosphodiesterase type 5 inhibitors enhance chemotherapy in preclinical models of esophageal adenocarcinoma by targeting cancer-associated fibroblasts. CAFs, EACs, TME
16  2022 Phosphodiesterase-5 Inhibitor Attenuates Anxious Phenotypes and Movement Disorder Induced by Mild Ischemic Stroke in Rats. SIL
17  2022 Pulmonary Vasculature Responsiveness to Phosphodiesterase-5A Inhibition in Heart Failure With Reduced Ejection Fraction: Possible Role of Plasma Potassium. CO, HF, LVAD, PH, PVR, RHC, TPG
18  2022 Repurposing PDE5 inhibitor tadalafil and sildenafil as anticancer agent against hepatocellular carcinoma via targeting key events of glucose metabolism and multidrug resistance. HCC, MDR
19  2022 Testosterone recovery therapy targeting dysfunctional Leydig cells. ED
20  2022 The management of erectile dysfunction in men with diabetes mellitus unresponsive to phosphodiesterase type 5 inhibitors. ED
21  2022 The role of testosterone in male sexual function. ED, TRT
22  2022 The Sexual Goals of Metoidioplasty Patients and Their Attitudes Toward Using PDE5 Inhibitors and Intracavernosal Injections as Erectile Aids. EHS, ICI, TM
23  2022 Urological Society of Australia and New Zealand (USANZ) and Australasian Chapter of Sexual Health Medicine (AChSHM) for the Royal Australasian College of Physicians (RACP) clinical guidelines on the management of erectile dysfunction. AChSHM, ED, LOE, RACP, USANZ
24  2022 [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis]. 6MWD, AEs, CIs, ERA, ERAs, FC, ORs, PAH, SAE, SUCRA, WMDs
25  2021 A case report of pudendal arteries angioplasty with sirolimus drug-coated balloon and drug-eluting stent associated with intracavernous autologous peripheral blood mononuclear cells injection for untreatable vasculogenic erectile dysfunction. ED, IC, ID, PBMNCs, PDE1
26  2021 Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. MI
27  2021 Benign prostatic hyperplasia/obstruction ameliorated using a soluble guanylate cyclase activator. BOO, BPH, CYB5R3, LUTS, sGC
28  2021 Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review. B3AR, BPH, QoL
29  2021 Bilateral neurosensory retinal detachment secondary to tadalafil treatment. NRD, OCT
30  2021 Cardiovascular Outcome Risks in Patients With Erectile Dysfunction Co-Prescribed a Phosphodiesterase Type 5 Inhibitor (PDE5i) and a Nitrate: A Retrospective Observational Study Using Electronic Health Record Data in the United States. CV, ED
31  2021 Clinical efficiency of combination therapy using testosterone replacement therapy, phosphodiesterase 5 inhibitors and Kampo herbal medicine for eugonadal patients with late-onset hypogonadism syndrome. AMS, FT, LOH, T enanthate, TRT
32  2021 Combination Therapy in Pulmonary Arterial Hypertension-Targeting the Nitric Oxide and Prostacyclin Pathways. ERAs, NO, PAH, sGC
33  2021 Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats. ASD, DSC, ED, FTIR, SEM, TDL, XRD
34  2021 Effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews and meta-analyses. ---
35  2021 Effect of Tadalafil Administration on Redox Homeostasis and Polyamine Levels in Healthy Men with High Level of Physical Activity. CAT, CK, FTH, GPx, LDH, PrCAR, SOD, Spd, Spm, TAC, TBARS
36  2021 Efficacy and Safety of Avanafil in Chinese Subjects With Erectile Dysfunction: A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled Phase III Clinical Trial. ED, EF, IIEF, TEAEs
37  2021 Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis. AEs, ERA, mPAP, PAH, ProsA, SAEs, WHO-FC
38  2021 Efficacy of Penile Low-Intensity Shockwave Therapy and Determinants of Treatment Response in Taiwanese Patients with Erectile Dysfunction. ED, EHS, Li-ESWT, MCID, QoL
39  2021 Erectile dysfunction treatment with Phosphodiesterase-5 Inhibitors: Google trends analysis of last 10 years and COVID-19 pandemic. AAPC, ED, FDA, GT, RSV
40  2021 Mirabegron improves erectile function in men with overactive bladder and erectile dysfunction: a 12-week pilot study. ED, HRQL, IIEF, OAB-q
41  2021 Muscle Damage in Systemic Sclerosis and CXCL10: The Potential Therapeutic Role of PDE5 Inhibition. CK, CXCL10, JNK, NF-kappaB, SSc, STAT1
42  2021 Penile Hemodynamic Response to Phosphodiesterase Type V Inhibitors after Cavernosal Sparing Inflatable Penile Prosthesis Implantation: A Prospective Randomized Open-Blinded End-Point (PROBE) Study. ICI, PROBE
43  2021 Penile Rehabilitation and Treatment Options for Erectile Dysfunction Following Radical Prostatectomy and Radiotherapy: A Systematic Review. ED, RCT, RP, RT
44  2021 Phosphodiesterase 5 Inhibitor Use in Patients Undergoing Decompression Surgery for Lumbar Spinal Stenosis. LDS, LSS
45  2021 Phosphodiesterase-5 Inhibitors and Outcomes During Left Ventricular Assist Device Support: A Systematic Review and Meta-Analysis. CI, LVAD, OR
46  2021 Randomized Placebo Controlled Trial of Sildenafil Citrate, Cognitive Behavior Sex Therapy and Integrated Treatment in Men Diagnosed With Non Organic Erectile Dysfunction. CBST, DASS-21, IIEF-5, NOED, SC
47  2021 Safety and tolerability of combination therapy with ambrisentan and tadalafil for the treatment of pulmonary arterial hypertension in children: Real-world experience. ERA, PH
48  2021 Sexual function in men undergoing androgen deprivation therapy. ADT
49  2021 Sildenafil Alleviates Murine Experimental Autoimmune Encephalomyelitis by Triggering Autophagy in the Spinal Cord. CNS, EAE, MS
50  2021 Sildenafil augments fetal weight and placental adiponectin in gestational testosterone-induced glucose intolerant rats. IUGR, Nrf2, TyG
51  2021 Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial. 6MWD, OR, PAH
52  2021 The Efficacy and Safety of Pulmonary Vasodilators in Pediatric Pulmonary Hypertension (PH): A Systematic Review and Meta-analysis. ERAs, PH, POPH, PPAH, PPHN
53  2021 The mitochondrial regulator PGC1α is induced by cGMP-PKG signaling and mediates the protective effects of phosphodiesterase 5 inhibition in heart failure. PGC-1alpha
54  2021 Topically delivered nitric oxide acts synergistically with an orally administered PDE5 inhibitor in eliciting an erectile response in a rat model of radical prostatectomy. CN, ED, NO-MP, RP
55  2020 A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure. eNOS, NOX, VEGF
56  2020 Acute Unloading Effects of Sildenafil Enhance Right Ventricular-Pulmonary Artery Coupling in Heart Failure. PA, PAWP, RV
57  2020 Advantages of Phosphodiesterase Type 5 Inhibitors in the Management of Glucose Metabolism Disorders: A Clinical and Translational Issue. ED
58  2020 An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance. ED, ESHI
59  2020 Anterior resection of the rectum vs radical prostatectomy. Are there any differences in sexual rehabilitation? ARR, ED, RP
60  2020 Association between sexual activity-related death and non-prescription use of phosphodiesterase type 5 inhibitors. ---
61  2020 Comparative efficacy and safety of drug treatment for premature ejaculation: A systemic review and Bayesian network meta-analysis. ---
62  2020 Considerations for prescribing pharmacotherapy for the treatment of erectile dysfunction. ED
63  2020 Correcting imbalance of sex hormones by a phosphodiesterase 5 inhibitor improves copulatory dysfunction in male rats with type 2 diabetes. LETO, LH, OLETF
64  2020 Do Urologists Really Recognize the Association Between Erectile Dysfunction and Cardiovascular Disease? CVDs, ED
65  2020 Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis. 6MWD, CFE, CTD-PAH, ERA, OR
66  2020 Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. ---
67  2020 Erectile disfunction medical treatment with phosphodiesterase 5 inhibitors (PDE5i) in patients with retinitis pigmentosa and side effects. ---
68  2020 Erectile Dysfunction after Kidney Transplantation. ---
69  2020 Evaluation of combined therapeutic effects of hydrogen sulfide donor sodium hydrogen sulfide and phosphodiesterase type-5 inhibitor tadalafil on erectile dysfunction in a partially bladder outlet obstructed rat model. ED, NOS, PBOO
70  2020 Factors Associated With Potentially Inappropriate Phosphodiesterase-5 Inhibitor Use for Pulmonary Hypertension in the United States, 2006 to 2015. ORs, PH, VA
71  2020 Identifying potential parameters associated with response to switching from a PDE5i to riociguat in RESPITE. GDF15, RRS
72  2020 Long-term effectiveness and predictors of success of low-intensity shockwave therapy in phosphodiesterase type 5 inhibitors non-responders. ED, EHS, IIEF-EF, LiSWT
73  2020 Low intensity shockwave therapy in combination with phosphodiesterase-5 inhibitors is an effective and safe treatment option in patients with vasculogenic ED who are PDE5i non-responders: a multicenter single-arm clinical trial. ED, Li-ESWT, PDU
74  2020 Management of erectile dysfunction following robot-assisted radical prostatectomy: a systematic review. RARP
75  2020 Oral Testofen, L-Citrulline, Resveratrol, and Caffeine Supplement Drink Improves Sexual Function in Men with Phosphodiesterase 5 Inhibitors: Randomized, Double-Blind, Placebo-Controlled Crossover Pilot Study. IIEF
76  2020 Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. ED, Li-ESWT
77  2020 Phosphodiesterases 5 Inhibitors and Erectile Dysfunction Recovery after Pelvic Surgery: Future Perspectives for New Drugs and New Formulations. ED
78  2020 Placebo Responses Among Men With Erectile Dysfunction Enrolled in Phosphodiesterase 5 Inhibitor Trials: A Systematic Review and Meta-analysis. ED, PRISMA
79  2020 Protective and therapeutic effects of sildenafil and tadalafil on aflatoxin B1-induced hepatocellular carcinoma. AFB1, HCC
80  2020 Retrospective comparison of focused shockwave therapy and radial wave therapy for men with erectile dysfunction. ED, F-SWT, rWT, SHIM, SWT
81  2020 Retrospective Database Analysis of Treatment Patterns Among Patients with Pulmonary Arterial Hypertension. ERS, ESC, MAPD, PAH
82  2020 Role of identified noncoding RNA in erectile dysfunction. ED, lncRNAs, miRNAs, ncRNAs
83  2020 Sildenafil Reduces Expression and Release of IL-6 and IL-8 Induced by Reactive Oxygen Species in Systemic Sclerosis Fibroblasts. ROS, RP, SSc
84  2020 The Association of Phosphodiesterase 5 Inhibitor on Ischemia-Reperfusion Induced Kidney Injury in Rats. ICAM-1, IR, MCP-1
85  2020 The incidence rate of pulmonary arterial hypertension and scleroderma renal crisis in systemic sclerosis patients with digital ulcers on endothelin antagonist receptors (ERAs) and phosphodiesterase-5 inhibitors (PDE5i). DU, ERAs, PAH, SRC, SSc-DU
86  2020 The medical and surgical treatment of erectile dysfunction: a review and update. ED
87  2020 The Phosphodiesterase Type 5 Inhibitor Sildenafil Improves DNA Stability and Redox Homeostasis in Systemic Sclerosis Fibroblasts Exposed to Reactive Oxygen Species. ROS, SSc
88  2020 The Role of Testosterone in Amplifying the Effect of a Phosphodiesterase Type 5 Inhibitor After Pelvic Irradiation. eNOS, nNOS
89  2020 The Role of the Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation After Radical Prostatectomy: A Randomized Clinical Trial. ED, Li-ESWT, RP
90  2020 Thinking About Pathomechanisms and Current Treatment of Erectile Dysfunction-"The Stanley Beamish Problem." Review, Recommendations, and Proposals. ---
91  2020 Treatment of pulmonary hypertension with riociguat: a review of current evidence and future perspectives. CTEPH, PAH, PEA, PH, sGC
92  2020 [Pulmonary arterial hypertension (PAH ) : a new era of pulmonary arterial vasodilatators]. cGMP, ERA, PAH
93  2020 [Tadalafil 5 mg once daily is a rationale option for simultaneous treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction]. BPH, ED, LUTS
94  2019 A purely penoscrotal approach: Reservoir placement of an inflatable penile prosthesis (IPP) in an orthotopic neobladder patient. Case report. IPP, PGE2
95  2019 Acute Hemodynamic Changes after Single Administration of Udenafil in Pulmonary Arterial Hypertension: a Phase IIa Study. CI, mPAP, MSAP, PAH, PAWP, PVRI
96  2019 An Evaluation of a Clinical Care Pathway for the Management of Men With Nonorganic Erectile Dysfunction. ED, ICI
97  2019 Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. ED, LOH, NO, TRT
98  2019 Combination Therapy with Alpha-blocker and Phosphodiesterase-5 Inhibitor for Improving Lower Urinary Tract Symptoms and Erectile Dysfunction in Comparison with Monotherapy: A Systematic Review and Meta-analysis. CI, ED, IIEF, IPSS, LUTS, MDs, PRISMA, PVR
99  2019 Current diagnosis and management of erectile dysfunction. ED
100  2019 Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction? ED